Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
STEAP1 is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. Additionally we are shipping STEAP1 Kits (5) and STEAP1 Proteins (4) and many more products for this protein.
Showing 10 out of 136 products:
Human Polyclonal STEAP1 Primary Antibody for EIA, IHC (p) - ABIN500817
Ohgami, Campagna, McDonald, Fleming: The Steap proteins are metalloreductases. in Blood 2006
Show all 4 references for ABIN500817
Human Polyclonal STEAP1 Primary Antibody for EIA, IHC (p) - ABIN500819
Ohgami, Campagna, Greer, Antiochos, McDonald, Chen, Sharp, Fujiwara, Barker, Fleming: Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. in Nature genetics 2005
Show all 3 references for ABIN500819
Human Monoclonal STEAP1 Primary Antibody for EIA, IF - ABIN317568
Rodeberg, Nuss, Elsawa, Celis: Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. in Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Show all 2 references for ABIN317568
Human Polyclonal STEAP1 Primary Antibody for WB - ABIN610692
Drees, Friederich, Fradelizi, Louvard, Beckerle, Golsteyn: Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins. in The Journal of biological chemistry 2000
Show all 2 references for ABIN610692
Human Polyclonal STEAP1 Primary Antibody for IHC (p), WB - ABIN318890
Alves, Faure, Graff-Dubois, Cornet, Bolonakis, Gross, Miconnet, Chouaib, Fizazi, Soria, Lemonnier, Kosmatopoulos: STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. in Cancer immunology, immunotherapy : CII 2006
Show all 2 references for ABIN318890
These findings highlight the ability of immuno-PET with (89)Zr-2109A to detect acute changes in STEAP1 expression
Data indicate that six transmembrane epithelial antigen of the prostate 1 (STEAP1) is consistently overexpressed in malignant prostate tissue, namely adenocarcinoma and prostatic intraepithelial neoplasia (PIN (show DYNLL1 Antibodies)) lesions.
The findings provide evidence that STEAP1 is a biomarker of worse prognosis in prostate carcinomas patients.
STEAP1 is down-regulated by dihydrotestosterone and estradiols in LNCaP cells and in rat prostate.
STEAP1 overexpression predicts improved outcome of Ewing's sarcoma patients, possibly due to enhanced sensitivity towards ROS (show ROS1 Antibodies)-generating chemotherapeutics.
EWS (show EWSR1 Antibodies)-FLI1 (show FLI1 Antibodies) mediated overexpression of STEAP1 increases the invasiveness and oxidative stress levels of Ewing tumor cells.
Studies suggest that activated human gammadelta T cells can efficiently present PRAME (show PRAME Antibodies) and STEAP1-derived epitopes and allow breaking tolerance against these tumor-associated self-antigens.
Data suggest that zoledronic acid may affect cancer cells also by targeting the gene expression of STEAP.
Peptide STEAP-292.2L (MLAVFLPIV) may have potential as an antitumor peptide vaccine.
STEAP mRNA is used here as a marker to evaluate biological samples from individuals suspected of having cancers, and may provide prognostic information useful in defining appropriate therapeutic options.
This gene is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. The gene product is predicted to be a six-transmembrane protein, and was shown to be a cell surface antigen significantly expressed at cell-cell junctions.
six transmembrane epithelial antigen of the prostate 1
, metalloreductase STEAP1-like
, metalloreductase STEAP1
, six-transmembrane epithelial antigen of prostate 1
, six transmembrane endothelial antigen of PAEC